ABSTRACT
In the present study, a comprehensive and sensitive method for simultaneous determination of 21 PIs (nine benzophenones, eight amine co-initiators, and four thioxanthones) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry was developed and validated. Two different pre-treatment approaches (liquid-liquid extraction (LLE) and LLE coupled with solid-phase extraction (SPE)) and eight extraction solvents were studied to optimize sample treatment to obtain good recoveries and reduce any matrix effects. The procedure of LLE+SPE was selected as final sample treatment procedure because it obtained higher recoveries as well as lower matrix effects than that performed by LLE alone. The recoveries of 21 target analytes at three spiked concentrations (0.05, 0.5, and 5 ng/mL) ranged from 81% to 109%. The intra- and inter-day relative standard deviations were between 2.5% and 13%. Accuracy and precision data indicated that the detection method was accurate and precise for most of the PIs. The linearities of the labeled dilution calibration curves at 10 concentration levels (iLOQ to 100 ng/mL or iLOQ to 200 ng/mL) were good with correlation coefficients ranged from 0.995 to 0.999. The method quantification limits were in the range of 1.7-16 pg/mL. The analytical method was applied to the analysis of PIs in 14 human plasma samples collected from pregnant women in Guangdong Province, China. Fifteen PIs were detected with total concentrations ranging from 318 to 2772 pg/mL. The ubiquitous contamination of human plasma with PIs suggests that there is widespread exposure to these compounds. Consequently, there should be increased awareness of these pollutants in the environment.
Subject(s)
Benzophenones/blood , Chromatography, High Pressure Liquid/methods , Xanthones/blood , Adult , Benzophenones/isolation & purification , Benzophenones/standards , Chromatography, High Pressure Liquid/standards , Environmental Pollutants/blood , Female , Healthy Volunteers , Humans , Limit of Detection , Liquid-Liquid Extraction , Pregnancy , Quality Control , Solid Phase Extraction , Tandem Mass Spectrometry/methods , Tandem Mass Spectrometry/standards , Thioxanthenes/blood , Thioxanthenes/isolation & purification , Thioxanthenes/standards , Xanthones/isolation & purification , Xanthones/standardsABSTRACT
A simple, rapid and economical method was developed and validated for the analysis and quantification of 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5), a P-glycoprotein inducer/activator, in biological samples, using reverse-phase high-performance liquid chromatography (HPLC). A C18 column and a mobile phase composed of methanol-water (90/10, v/v) with 1% (v/v) triethylamine, at a flow rate of 1 mL/min, were used for chromatographic separation. TX5 standards (0.5-150 µm) were prepared in human serum. Methanol was used for TX5 extraction and serum protein precipitation. After filtration, samples were injected into the HPLC apparatus and TX5 was quantified by a conventional UV detector at 255 nm. The TX5 retention time was 13 min in this isocratic system. The method was validated according to ICH guidelines for specificity/selectivity, linearity, accuracy, precision, limits of detection and quantification (LOD and LOQ) and recovery. The method was proved to be selective, as there were no interferences of endogenous compounds with the same retention time of TX5. Also, the developed method was linear (r2 ≥ 0.99) for TX5 concentrations between 0.5 and 150 µm and the LOD and LOQ were 0.08 and 0.23 µm, respectively. The results indicated that the reported method could meet the requirements for TX5 analysis in the trace amounts expected to be present in biological samples.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B/agonists , Chromatography, High Pressure Liquid/methods , Chromatography, Reverse-Phase/methods , Xanthones/blood , Humans , Limit of Detection , Thioxanthenes/bloodABSTRACT
A simple and reliable HPLC method was developed for the estimation of a new anti-cancer agent that belongs to the thioxanthone class, SR271425 in mouse plasma. SR271425, it's metabolites and internal standard (SR233377) were separated from plasma by liquid-liquid extraction using dichloromethane after quenching the plasma proteins with acetonitrile. Chromatography was performed on a reversed-phase C18 column using methanol-10 mM phosphate buffer, pH 3.5 (45:55) as mobile phase at a flow-rate of 0.8 ml/min for first 10 min and 1.4 ml/min for the next 15 min with UV-Vis detection at 264 nm and SR233377 as internal standard. The retention times of SR271425 and internal standard were 18.6 and 14.8 min, respectively. The limit of detection was 40 ng/ml and the limit of quantification was 78 ng/ml. This method was also able to detect the three metabolites of SR271425. The intra- and inter-day relative standard deviations were less than 13% at all concentrations. This analytical method was precise and reproducible for pharmacokinetics and metabolism studies of the drug in mice. SR271425 is proceeding to phase I clinical trials in 2001.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Chromatography, High Pressure Liquid/methods , Thioxanthenes/pharmacokinetics , Animals , Antineoplastic Agents/blood , Mice , Reference Standards , Reproducibility of Results , Spectrophotometry, Ultraviolet , Thioxanthenes/bloodABSTRACT
A simple and highly sensitive method is proposed for the fluorimetric determination of four thioxanthene derivatives, namely: chlorprothixene, clopenthixol, flupentixol and thiothixene, in dosage forms and biological fluids. The method involves the use of nitrous acid as an oxidant to produce the corresponding fluorescent thioxanthenone sulphoxides. The experimental parameters were carefully studied and incorporated into the procedures. The results obtained compare favourably with those obtained by the official methods. The concentration-fluorescence plots were rectilinear over the range of 0.04-0.4 microg/ml for thiothixene, and 0.02-0.25 microg/ml for the other compounds, with minimum detectability (S/N = 2) of 2 ng/ml for all the studied compounds except thiothixene which was 4 ng/ml. The proposed method was applied to the determination of the studied compounds in dosage forms. The results obtained were in good agreement with those obtained adopting the USP XIII method. The proposed method was further applied to the determination of flupentixol in spiked human urine and plasma, the percentage recoveries were 94.39 +/- 1.81 and 96.46 +/- 0.28, respectively. A proposal of the reaction pathway was presented.
Subject(s)
Dosage Forms , Spectrometry, Fluorescence/methods , Thioxanthenes/analysis , Humans , Thioxanthenes/blood , Thioxanthenes/urineABSTRACT
Two new thioxanthenones, 183577 and 232759, have rekindled interest in the development of representatives from this class of structures as useful anticancer agents. Although the mechanism of action is unknown, both compounds demonstrated a similar spectrum of solid tumor selectivity. 232759 was selected for clinical development because it showed no hepatotoxicity in preliminary studies, whereas 183577 showed hepatotoxicity but only at the maximum tolerated dose (MTD). The limiting toxicity for the clinical candidate was myelosuppression in preliminary studies. Plasma and tissue drug levels, as well as protein binding, were studied in mice using optimal administration times at the MTD for each drug (for 183577, this was a 4-h infusion at 1350 mg/m2 and for 232759, it was a 5-min injection at 240 mg/m2), as well as at one-half the MTD for the clinical candidate. The drugs were 96-100% bound by plasma proteins. The peak drug concentrations, half-life, and area under the concentration-time curve in plasma for 183577 were 3483 ng/ml, 465 min, and 2018 microgram/ml. min, respectively. The peak drug concentration, half-life, and area under the concentration-time curve in plasma for 232759 were 5257 ng/ml, 44 min, and 276 microgram/ml. min, respectively, at the MTD and 2810 ng/ml, 40 min, and 110 microgram/ml. min at one-half the MTD. In all instances of simultaneous measurements, drug concentrations were equal or higher in tissues than they were in plasma. Unlike the plasma and kidney concentrations of 183577, the liver concentrations did not show a declining trend over the 8-h observation period. Declines in plasma, liver, kidney, and tumor levels of 232759 were detected over the 8-h observation period. The sustained high 183577 concentration in liver is believed to be responsible for its prolonged half-life and hepatotoxicity. Evidence for metabolism of the parent drugs was based on the finding of additional peaks on the high-pressure liquid chromatography tracings. Future studies will focus on identification and antitumor studies of these presumed metabolites in hopes of a better understanding of the solid tumor activity profiles and toxic effects of these compounds.
Subject(s)
Adenocarcinoma/metabolism , Antineoplastic Agents/pharmacokinetics , Colonic Neoplasms/metabolism , Sulfonamides/pharmacokinetics , Thioxanthenes/pharmacokinetics , Adenocarcinoma/blood , Animals , Antineoplastic Agents/blood , Antineoplastic Agents/therapeutic use , Blood Proteins/metabolism , Colonic Neoplasms/blood , Female , Half-Life , Kidney/metabolism , Leukemia L1210/blood , Leukemia L1210/metabolism , Liver/metabolism , Metabolic Clearance Rate , Mice , Mice, Inbred Strains , Sulfonamides/blood , Sulfonamides/therapeutic use , Thioxanthenes/blood , Thioxanthenes/therapeutic use , Tissue DistributionABSTRACT
Results are presented of a liquid chromatographic-thermospray tandem mass spectrometric method of analysing different drugs in whole blood. Substances with hypnotic, sedative and tranquillising properties from the benzodiazepine, the thioxanthene, the butyrophenone, the methadone and the diphenylbutylpiperidine groups were investigated. It appears that ten to hundred times lower detection limits for the substances in whole blood can be reached with this method compared with methods more commonly used. Detection limits in the range 10-100 pg per injection (equivalent to 0.05-0.5 ng/ml whole blood) were reached for the majority of the compounds.
Subject(s)
Benzodiazepines/blood , Butyrophenones/blood , Chromatography, High Pressure Liquid/methods , Mass Spectrometry/methods , Methadone/blood , Narcotics/blood , Piperidines/blood , Thioxanthenes/blood , Calibration , Humans , Sensitivity and SpecificityABSTRACT
WIN 33377 (I) is a member of a novel class of cytotoxic antitumor agents, 4-aminomethyl thioxanthone derivatives. A simple, rapid and reproducible method has been developed for the assay of I in mouse plasma using a high-performance liquid chromatographic method utilizing a column-switching technique. The method involves direct injection of buffered plasma to the extraction column for sample clean-up followed by switching onto an analytical column for analysis with UV detection at 256 nm. The method has demonstrated accuracy and precision over the range 10-2500 ng/ml using a 100-microliters plasma sample with a minimum quantifiable level at 10 ng/ml. Stability of mouse plasma samples was demonstrated after storage for 4 weeks at -15 to -20 degrees C, as was the ability of samples to be accurately quantified after a maximum of three freeze-thaw cycles. Recovery was greater than 87% for the compound and the internal standard. The assay was accurate and reproducible with measured values lying within the limits of defined acceptance criteria. The utility of the method was demonstrated by analyzing plasma samples obtained from mice dosed with I as part of a pre-clinical safety study intended to assist in the design of a pharmacokinetically guided dose escalation strategy.
Subject(s)
Antineoplastic Agents/blood , Chromatography, High Pressure Liquid/methods , Sulfonamides/blood , Thioxanthenes/blood , Animals , Antineoplastic Agents/pharmacokinetics , Mice , Reference Standards , Reproducibility of Results , Spectrophotometry, Ultraviolet , Sulfonamides/pharmacokinetics , Thioxanthenes/pharmacokineticsABSTRACT
24 patients have been treated with cis(z)-flupenthixol decanoate for 6-12 months. Intramuscular injections were given about every 3 weeks. Before treatment and on each day of injection the mental state was assessed by BPRS and registration of side effects was performed. Blood samples were taken 7 days after each injection and on the last day of the dosage interval. Neuroleptic activity was determined in serum by RRA and expressed in cis(z)-flupenthixol equivalents. The drug level was significantly correlated to the dose. No clear relationship between drug level and clinical results as well as side effects was found. Less pronounced variations of the drug level between subsequent injections resulted in a positive therapeutic response.
Subject(s)
Flupenthixol/blood , Radioligand Assay , Schizophrenia/drug therapy , Thioxanthenes/blood , Adult , Female , Flupenthixol/administration & dosage , Flupenthixol/analogs & derivatives , Flupenthixol/therapeutic use , Humans , Injections , Male , Middle AgedABSTRACT
Steady-state plasma concentrations of cis(Z)-flupentixol (active principle) and trans(E)-flupentixol (inactive) were measured in 41 patients at least on one occasion. Results indicate that concentrations of the trans-isomer are significatively higher. This demonstrates that the two isomers are not handled in the same way by the organism. This may be relevant if plasma level monitoring is performed using non-specific analytical methods.
Subject(s)
Flupenthixol/blood , Schizophrenia/blood , Thioxanthenes/blood , Chromatography, High Pressure Liquid , Humans , Isomerism , Monitoring, Physiologic , Radioimmunoassay , Structure-Activity RelationshipABSTRACT
Combined liquid chromatography and mass spectrometry (LC/MS) with a moving belt interface can be used as a rapid method for the determination of bromazepam, clopenthixol, and reserpine in serum samples obtained from cases of acute overdoses with combinations of these drugs. Low resolution detection limits are about 100 pg for the three drugs, while in high resolution mode the detection limit for bromazepam is shown to be at least 35 pg. Accurate masses were obtained in a serum sample within 5 ppm using high voltage scanning over a narrow mass range for about 10 ng of bromazepam and clopenthixol, respectively. Chemical deactivation of the belt was shown to effectively reduce memory effects and to improve the desorption characteristics of the belt leading to higher yields of evaporated intact molecules.
Subject(s)
Anti-Anxiety Agents/blood , Bromazepam/blood , Clopenthixol/blood , Reserpine/blood , Thioxanthenes/blood , Bromazepam/poisoning , Chromatography, Liquid , Clopenthixol/poisoning , Humans , Mass Spectrometry , Reserpine/poisoningABSTRACT
Recent studies have shown that the interaction of various tricyclic neuroleptics and antidepressants with isolated alpha 1-acid glycoprotein occurs at one common binding site and with relatively high association constants. The aim of the present study was to find differences in the binding of some phenothiazines, thioxanthenes, and several other drugs reported to bind alpha 1-AGP. The findings suggest that the affinity of the phenothiazines and thioxanthenes depends primarily on the existence of the tricyclic skeleton and is generally increased by the basic side chain. Substituents at position 3 of the phenothiazine nucleus influence the affinity in a variable way. The losses of radioactivity by non-specific absorptions to the dialysing chambers were considered for the calculation of the association constants. No correlation between association constants and the antipsychotic potency of neuroleptic drugs could be detected.
Subject(s)
Orosomucoid/metabolism , Psychotropic Drugs/blood , Antidepressive Agents, Tricyclic/blood , Antipsychotic Agents/blood , Binding, Competitive , In Vitro Techniques , Phenothiazines , Protein Binding/drug effects , Thioxanthenes/bloodSubject(s)
Antipsychotic Agents/classification , Schizophrenia/drug therapy , Antipsychotic Agents/blood , Antipsychotic Agents/therapeutic use , Benzamides/blood , Benzamides/therapeutic use , Butyrophenones/blood , Butyrophenones/therapeutic use , Dibenzoxazepines/therapeutic use , Humans , Phenothiazines/therapeutic use , Piperidines/therapeutic use , Thioxanthenes/blood , Thioxanthenes/therapeutic useABSTRACT
Twenty-six chronic schizophrenic patients on well established depot neuroleptic regimes with stable doses (16 on fluphenazine decanoate, ten on flupenthixol decanoate) had serum neuroleptic levels measured by a radioreceptor assay (RRA) method. The assay was sufficiently sensitive to measure serum levels in all cases, with acceptable levels of inter-assay variation. Blood level measurements were repeated on two occasions, at the same time interval from the last injection, in 18 patients (11 on fluphenazine decanoate, seven on flupenthixol decanoate) and remained reasonably stable in most cases, although others showed a wider variation. Despite a wide range of doses (X 32 fluphenazine decanoate, X 21 flupenthixol decanoate) the serum levels fell in a remarkably narrow range (X 4, X 6). There was a significant correlation between dose and blood level for flupenthixol decanoate, but not for fluphenazine decanoate.
Subject(s)
Flupenthixol/blood , Fluphenazine/blood , Schizophrenia/blood , Thioxanthenes/blood , Adult , Delayed-Action Preparations , Female , Flupenthixol/therapeutic use , Fluphenazine/therapeutic use , Humans , Male , Middle Aged , Schizophrenia/drug therapyABSTRACT
A new method of measuring flupentixol in plasma was developed using gas chromatography (GC) with a nitrogen-phosphorus detector. The minimal quantifiable concentration was 0.5 ng/ml and the day-to-day coefficient of variation was 9.4% at 2 ng/ml. A comparison of flupentixol concentrations measured with radioimmunoassay (RIA) and GC was undertaken on 100 plasma samples obtained from 50 schizophrenic patients. The RIA method tended to overestimate flupentixol concentrations compared with GC. The reasons for this discrepancy might be the presence in plasma of the inactive trans(E)-flupentixol isomer and metabolites of flupentixol, which would cross-react with the antibody. The results of this study show that GC can be used for therapeutic monitoring of flupentixol.
Subject(s)
Flupenthixol/blood , Schizophrenia/blood , Thioxanthenes/blood , Administration, Oral , Adolescent , Adult , Chromatography, Gas , Delayed-Action Preparations , Female , Flupenthixol/administration & dosage , Flupenthixol/therapeutic use , Humans , Male , Middle Aged , Radioimmunoassay , Schizophrenia/drug therapyABSTRACT
Twenty-three acutely psychotic inpatients treated with flupentixol were included in the study. Steady-state plasma concentrations were compared with therapeutic outcome in a routine clinical setting. The threshold concentration for satisfactory antipsychotic effect appeared to be approximately 2 ng/ml. Controlled studies are needed to establish the existence and exact limits of a therapeutic window.
Subject(s)
Flupenthixol/blood , Schizophrenia/drug therapy , Thioxanthenes/blood , Acute Disease , Administration, Oral , Adolescent , Adult , Chromatography, Gas , Female , Flupenthixol/therapeutic use , Humans , Male , Middle Aged , Schizophrenia/bloodABSTRACT
Whole blood and plasma concentrations of active neuroleptic drugs were measured in eight schizophrenic outpatients who had received cis(Z)-clopenthixol decanoate in Viscoleo or fluphenazine decanoate in sesame oil by intramuscular injection. Whole blood and plasma concentrations were very similar, though there was a slight tendency for blood concentrations to be higher than plasma concentrations. Maximum concentrations appeared at 1 week after administration of cis(Z)-clopenthixol decanoate, whereas the highest concentrations after fluphenazine decanoate were seen at the end of the 3-week dosage interval. Some between-individual variation and a limited within-individual variation was seen.
Subject(s)
Antipsychotic Agents/blood , Clopenthixol/blood , Fluphenazine/analogs & derivatives , Schizophrenia/blood , Thioxanthenes/blood , Adult , Antipsychotic Agents/administration & dosage , Clopenthixol/administration & dosage , Clopenthixol/analogs & derivatives , Delayed-Action Preparations , Fluphenazine/administration & dosage , Fluphenazine/blood , Humans , Injections, Intramuscular , Kinetics , Male , Middle Aged , RadioimmunoassayABSTRACT
Using radioimmunoassay techniques, serum levels of depot neuroleptics, fluphenazine and flupenthixol, were estimated in two groups of chronic schizophrenic patients with, and without, tardive dyskinesia. There were high significant difference in dose-related serum levels of either drug between the groups. The hypothesis that patients with tardive dyskinesia develop the syndrome because they do not metabolise neuroleptics as efficiently as those without the syndrome was not supported by the data.
Subject(s)
Dyskinesia, Drug-Induced/blood , Flupenthixol/blood , Fluphenazine/blood , Schizophrenia/blood , Thioxanthenes/blood , Dyskinesia, Drug-Induced/etiology , Female , Flupenthixol/therapeutic use , Fluphenazine/therapeutic use , Humans , Male , Middle Aged , Schizophrenia/drug therapyABSTRACT
Cis(Z)-clopenthixol decanoate in Viscoleo (Sordinol Depot, Cisordinol Depot, Clopixol Inj.) was given intramuscularly to nine schizophrenic patients with dosage intervals of 1 or 2 weeks. Serum concentrations of the two geometric isomers of clopenthixol and its N-dealkyl metabolite were recorded in two successive dosage intervals. Significant correlations were found for dose vs area under the serum concentration curve and vs serum concentrations measured on individual days. The last mentioned concentrations are good measures of the area under the serum concentration curve, which expresses the drug load of the patient. The serum concentration curves in two successive dosage intervals were very similar. Maximum serum concentration was seen 5-7 days after injection and the mean maximum/minimum fluctuation was 1.6 with the 2-week dosage interval. The finding of very low amounts of the trans(E)-isomers of clopenthixol and the N-dealkyl-metabolite shows that isomerization of the cis(Z)-compounds into the corresponding trans(E)-isomers does not take place within the organism.
Subject(s)
Clopenthixol/blood , Clopenthixol/metabolism , Thioxanthenes/blood , Thioxanthenes/metabolism , Adult , Aged , Clopenthixol/analogs & derivatives , Dealkylation , Delayed-Action Preparations , Female , Humans , Kinetics , Male , Middle Aged , StereoisomerismABSTRACT
An assay strategy for determining a wide range of phenothiazine, thioxanthene and butyrophenone neuroleptics and antihistamines both alone and in combination in blood and plasma is described. The general method employs liquid chromatography with both conventional and radial compression nitrile bonded columns. Detection is by ultraviolet absorption spectrophotometry or by amperometry depending on the concentrations to be measured. Ultraviolet absorption is suitable down to 10 ng/ml. Below this level amperometry is preferable. The various compounds are used as internal standards for each other. The lower limit of detection is approximately 0.1 ng ml-1 with 10-ml sample. The with-run coefficient of variation is a maximum of 7.3%.